Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Penpulimab and Anlotinib with Chemotherapy in Perioperative Esophageal Cancer
NCT06586242Phase 2Recruiting
- Sponsor
- Xijing Hospital
- Start
- Apr 2023
- Primary completion
- Apr 2025
- Modality
- Small Molecules, Immune Checkpoint Inhibitors
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of penpulimab and anlotinib in esophageal cancer (2 arms), sponsored by Xijing Hospital. Primary endpoint: Pathological Complete Response Rate at 2 years. Started Apr 2023; status: recruiting.
02
Drugs
penpulimabanlotinib
03
Conditions
esophageal cancer
Beyond the preview
Go deeper on NCT06586242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06586242.